Reassessing the cardiovascular risks and benefits of thiazolidinediones

Clinical Cardiology

Volumn 31, Issue 9, 2008, Pages 397-403

  Zinn, Andrew ^a   Felson, Sabrina ^a   Fisher, Edward ^a   Schwartzbard, Arthur ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular outcomes; Diabetes mellitus; Insulin resistance; Metabolic syndrome; Peroxisome proliferator activated receptor gamma agonists; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ATORVASTATIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FIBRIC ACID DERIVATIVE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PRAMLINTIDE; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; TROGLITAZONE;

ADD ON THERAPY; ARTERY DIAMETER; ARTERY INTIMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL TRIAL; CORONARY STENT; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 53049107359     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20312     Document Type: Review

References (37)

1. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR: Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005;149(1):33-45
2. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 2002;287(3):356-359
3. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR: Metabolic syndrome: evaluation of pathological and therapeutic outcomes. Am Heart J 2005;149(1):20-32
4. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75(3):473-486
5. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004;351(11): 1106-1118
6. Blaschke P, Takata Y, Caglayan E, Law RE, Hsueh WA: Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006;26(1):28-40
7. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, et al.: Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26(3):624-630
8. Group TDCaCTR: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14):977-986
9. Group UPDSK: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-853
10. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643-2653
11. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, et al.: Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006; 152(1): 27-38
12. Group UPDSK: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-865
13. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, et al.: Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the national heart care project. Diabetes Care 2005;28(7):1680-1689
14. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, et al.: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111(5):583-590
15. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83(5): 1818-1820
16. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86(7):3452-3456
17. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, et al.: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111(19): 2525-2531
18. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296(21):2572-2581
19. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004;24(5):930-934
20. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, et al.: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003; 146(2):E5
21. Takagi T, Akasaka T, Yamamuro A, Honda Y, Morioka S, et al.: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000;36(5):1529-1535
22. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, et al.: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002;89(3):318-322
23. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, et al.: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27(11): 2654-2600
24. Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, et al.: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005;112(18):2792-2798
25. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. [see comment]. Lancet 2005; 366(9493): 1279-1289
26. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J, et al.: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004;47(9):1519-1527
27. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368(9541):1096-1105
28. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, et al.: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355(15):1551- 1562
29. Lonn E: Effects of ramipril and rosiglitazone on atherosclerosis: The study of atherosclerosis with ramipril and rosiglitazone. American College of Cardiology 2007 Scientific Sessions 2007
30. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-2471
31. Rosen CJ: The rosiglitazone story-lessons from an FDA advisory committee meeting. N Engl J Med 2007;357(9):844-846
32. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Dargie H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005;48(9):1726-1735
33. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28(7):1547-1554
34. Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, et al.: Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2004;26(3):379-389
35. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, et al.: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90(9):947-952
36. Magee MF, Isley WL, Investigators BDT: Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol 2006;97(12A):20G-30G
37. Lebovitz HE: Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. Endocr Pract 2006;12(Suppl 1):142-147